OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
A veteran in cell therapy and oncology commercialisation
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
CDSCO to fast-track trials and approval for COVID19 vaccine
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Subscribe To Our Newsletter & Stay Updated
